Introduction
According to “Assessment of Spondyloarthritis International Society (ASAS) classification criteria” (1), axial spondyloarthritis (axSpA) can be divided into two groups: patients with radiographic signs of sacroiliitis (ankylosing spondylitis, AS) and a group without radiographic sacroiliitis, the non-radiographic axial SpA (nr-axSpA) [
1].
Inflammatory back pain (IBP) is an important clinical symptom for axial involvement and is present in approximately 70% of patients diagnosed with axSpA [
1,
2].
Radiographic lesions usually develop several years after symptom onset, such as IBP, which can lead to a diagnostic delay of 5–10 years [
3]. This may result in subsequent undesired treatment delay, in particular in patients with nr-axSpA [
3]. A recent study revealed that approximately 5.1% of patients progress from nr-axSpA to AS in a 5-year period, especially in patients positive for the HLA-B27 antigen [
3,
4]. Active inflammatory lesions of the sacroiliac joints (SIJ), as defined by the ASAS group [
1], contribute to an earlier diagnosis of axial SpA.
One of the challenges of the current ASAS classification criteria of axial SpA is the large contribution of a positive MRI of the SI joints. However, many patients with high disease activity do not show active lesions at the MRI of the SI joints; approximately 59–64% is MRI-negative [
4,
5]. Therefore, we selected patients with inflammatory back pain with at least two SpA features, who might be prone to develop axial SpA, and repeated the MRI procedure after 6 months in case of a negative MRI (absence of active inflammation). In order to increase the chance of a positive MRI, all patients had to have a high disease activity score and should be eligible for treatment with a biological, which is in contrast with previous studies. A previous study showed an association between male gender and the chance at a positive MRI in IBP patients, but data on gender differences are scarce [
4].
Therefore, the primary aim of this study was to analyse the frequency of positive MRIs (both SIJ and spine) in IBP patients suspected of nr-axSpA with high disease activity. The secondary aims were to describe the progression of a negative MRI outcome at baseline after a 6-month follow-up, to describe the possible presence of structural lesions and to assess gender differences.
Results
In total, 70 patients were included in this study (Fig.
1), of whom 37 (53%) were female. The mean age at baseline was 34 years (Table
1). The first symptoms of back pain occurred at 4.7 years before diagnosis of IBP, at a mean age of 29 years. In total, 37 patients (53%) were HLA-B27 positive, of whom 18 were female (48.6%) and 19 were male (51.4%). In one female patient, HLA-B27 typing was not performed.
Table 1Patient characteristics of 70 non-radiographic axial SpA patients with high disease activity at baseline: comparison of positive and negative MRI SIJ and/or spine, stratified for sex
Demographics |
Male/female (%) | 47/53 | 55.6/44.4 | 42.9/57.1 | 0.3 (0.2; 1.6) |
Age (years)* | 34 (8.6) 35.8 (8.3)/32.1 (8.7) | 36.1 (8.1) 39.2 (7.3)/32.3 (7.6)¥ | 32.6 (8.8) 33.0 (8.2)/32.4 (9.4) | 0.1 (− 7.6; 0.76) |
Age onset back pain (years)* (N = 68) | 29 (9) 30.8 (9.0)/26.8 (8.8) | 30.9 (9.2) 34.0 (9.3)/27.5 (8.1) | 27.4 (8.8) 28.4 (8.3)/26.7 (9.4) | 0.1 (− 8.0; 1.1) |
Duration back pain (years)* (N = 68) | 4.7 (4.3) 4.3 (3.6)/5.0 (4.9) | 4.7 (4.5) 4.9 (3.9)/4.5 (5.3) | 4.8 (4.3) 3.9 (3.5)/5.4 (4.9) | 0.9 (− 2.1; 2.3) |
HLA-B27 positive (N = 69) | 36 (52.2) 19 (57.6)/18 (50.0) | 13 (50.0) 8 (53.3)/5 (45.5) | 13 (50.0) 11 (61.1)/12 (50.0) | 0.7 (0.3; 2.2) |
NSAID use | 37 (52.9) 16 (48.5)/21 (56.8) | 16 (59.3) 6 (40.0)/10 (83.3)¥ | 20 (47.6) 10 (55.6)/10 (41.7) | 0.3 (0.6; 4.3) |
SpA features |
Number SpA features* (mean) | 3 (1.1) 2.9 (0.9)/3.1 (1.2) | 3.0 (1.2) 2.9 (0.9)/3.1 (1.5) | 3.0 (1.0) 2.9 (1.0)/3.0 (1.1) | 1.0 (− 0.5; 0.6) |
Arthritis | 22 (31.4) 10 (30.3)/12 (32.4) | 7 (25.9) 5 (33.3)/2 (16.7) | 14 (33.3) 5 (27.8)/9 (37.5) | 0.5 (0.2; 2.0) |
Alternating buttock pain | 45 (64.3) 18 (54.5)/27 (73.0) | 20 (74.1) 10 (66.7)/10 (83.3) | 24 (57.1) 8 (44.4)/16 (66.7) | 0.2 (0.7; 6.2) |
Dactylitis | 5 (7.1) 2 (6.1)/3 (8.1) | 2 (7.4) 0/2 (16.7) | 3 (7.1) 2 (11.1)/1 (4.2) | 1.0 (0.2; 6.7) |
Thoracic pain (N = 69) | 45 (64.3) 21 (65.6)/24 (64.9) | 16 (59.3) 11 (73.3)/5 (41.7) | 29 (70.7) 10 (58.8)/19 (79.2) | 0.3 (0.2; 1.7) |
Enthesitis Achilles tendon | 17 (24.2) 8 (24.2)/9 (24.3) | 5 (18.5) 4 (26.7)/1 (8.3) | 11 (26.2) 4 (22.2)/7 (29.2) | 0.5 (0.2; 2.1) |
Enthesitis plantar fascia | 15 (21.4) 8 (24.2)/7 (18.9) | 6 (22.2) 3 (20.0)/3 (25.0) | 9 (21.4) 5 (27.8)/4 (16.7) | 0.9 (0.3; 3.4) |
Extra-articular symptoms |
Uveitis | 5 (7.1) 3 (9.1)/2 (5.4) | 2 (7.4) 2 (13.3)/0 | 3 (7.1) 1 (5.6)/2 (8.3) | 1.0 (0.2; 6.7) |
Inflammatory bowel disease | 3 (4.3) 2 (6.1)/1 (2.7) | 0 | 3 (7.1) 2 (11.1)/1 (4.2) | 0.2 (0.9; 1.0) |
Psoriasis | 8 (11.4) 5 (15.2)/3 (8.1) | 5 (18.5) 2 (13.3)/3 (25.0) | 3 (7.1) 3 (16.7)/0¥ | 0.2 (0.6; 13.6) |
Enthesitis | 29 (42.9) 16 (48.5)/13 (37.8) | 10 (37.0) 7 (46.7)/3 (25.0) | 19 (45.2) 9 (50.0)/10 (41.7) | 0.5 (0.3; 1.9) |
Family history |
Ankylosing spondylitis | 21 (30.0) 12 (36.4)/9 (24.3) | 8 (29.6) 6 (40.0)/2 (16.7) | 13 (31.0) 6 (33.3)/7 (29.2) | 0.9 (0.3; 2.7) |
Psoriasis | 12 (17.1) 3 (9.1)/9 (24.3) | 5 (18.5) 1 (6.7)/4 (33.3) | 7 (16.7) 2 (11.1)/5 (20.8) | 0.8 (0.3; 4.0) |
Inflammatory bowel disease | 6 (8.6) 1 (3.0)/5 (13.3) | 2 (7.4) 1 (6.7)/1 (8.3) | 4 (9.5) 0/4 (16.7) | 0.8 (0.1; 4.5) |
Uveitis | 2 (2.9) 1 (3.0)/1 (2.7) | 2 (5.6) 1 (5.0)/1 (6.3) | 0 | 0.2 (1.0; 1.1) |
Other patient features |
BASDAI (N = 61)* | 5 (2.0) 4.8 (2.0)/5.3 (2.1) | 4.9 (1.9) 4.4 (1.8)/5.7 (1.7) | 5.3 (2.1) 5.1 (2.1)/5.4 (2.1) | 0.5 (− 0.7; 1.4) |
BASMI (N = 48)* | 1.8 (1.2) 1.8 (1.3)/1.7 (1.1) | 1.7 (0.9) 1.8 (1.0)/1.6 (0.9) | 1.8 (1.4) 1.8 (1.5)/1.8 (1.2) | 0.9 (− 0.7; 0.7) |
Schober (cm) (N = 69)* | 4.4 (1.0) 4.4 (0.9)/4.4 (0.9) | 4.2 (0.9) 4.1 (0.9)/4.3 (1.1) | 4.5 (0.9) 4.7(0.9)/4.4 (0.9) | 0.2 (− 0.2; 0.7) |
SJC (N = 68)* | 0.2 (0.5) 0.3 (0.2)/0.3 (0.7)‡ | 0.2 (0.7) 0/0.5 (1.0) | 0.1 (0.4) 0.06 (0.2)/0.2 (0.5) | 0.5 (− 0.4; 0.2) |
TJC (N = 68)* | 2 (4) 2.1 (4.5)/1.8 (3.2) | 1.0 (2.2) 0.6 (2.3)/1.6 (0.9) | 2.6 (4.5) 3.4 (5.5)/2.0 (3.7) | 0.1 (− 0.0; 3.2) |
MASES (N = 67)* | 6.8 (7.4) 5.1 (7.4)/8.3 (7.2) | 3.8 (4.3) 2.2 (3.3)/5.8 (4.8)¥ | 9.1 (8.4) 7.7 (9.0)/10.1 (7.9) | 0.001 (2.1; 8.4)¥ |
ESR (mm/h) (N = 67)* | 10.7 (10) 7.2 (9.4)/13.6 (9.6) | 11.1 (10.9) 8.8 (12.1)/13.8 (9.2) | 10.3 (9.5) 5.8 (6.4)/13.5 (10.2)¥ | 0.8 (− 5.8; 4.3) |
CRP (mg/l) (N = 66)* | 3.7 (5.5) 2.6 (4.6)/4.6 (6.1) | 4.0 (6.0) 3.1 (5.6)/5.1 (6.5) | 3.6 (5.4) 2.2 (3.5)/4.8 (6.2) | 0.8 (− 3.2; 2.5) |
CRP (mg/l) elevated (%) | 22 (31.4) 9 (27.3)/13 (35.1) | 9 (39.1) 5 (33.3)/4 (33.3) | 13 (27.7) 4 (22.2)/9 (37.5) | 0.9 (0.4; 3.0) |
At baseline, peripheral joint symptoms were present in 31% of patients; 42.9% presented with enthesitis, mainly of the Achilles tendon, 7% experienced anterior uveitis and 11% had psoriasis. A positive family history of AS was present in 30% of the cases. Thirty-one percent had a raised CRP level (≥ 5.0 mg/l), and there was no significant difference in CRP between patients with a positive or negative MRI. The baseline characteristics did not show significant gender differences.
NSAIDs were used by half of the patients (52.9%) at baseline of whom 16 patients (59.3%) in the MRI-positive group and 20 patients (47.6%) in the MRI-negative group.
Unfortunately, in one patient, only MRI images of the spine were available and not of the SI joints because they were performed in another centre. So complete scoring sets of the MRI scans of the SIJ were available in 69 instead of 70 patients. Some of the patients refused MRI scans of the spine, mainly due to complaints of claustrophobia, resulting in a lower number of patients with baseline MRI of the spine (n = 47) compared with MRI of the SIJ (n = 69).
MRI at baseline
Overall, in 27 of 69 patients (38.6%), signs of inflammation were found at baseline MRI of the SIJ or spine whereas 42 patients (60.0%) had a negative MRI of both SIJ and spine (Table
2). Twenty-one out of 69 patients (30.4%) had a positive MRI of the SIJ, 9 out of 47 (19.1%) of the spine, of whom three patients (2.4%) had both. Male patients had more frequently a positive baseline MRI compared with female patients, 15 out of 33 male patients (45.5%) vs. 12 out of 37 female patients (33.3%) (OR = 0.58, 95% CI [0.2; 1.5],
p = 0.26) (Table
1). Imaging of the SIJ was repeated in 21 of the 41 patients who had a negative baseline MRI (51.2%), of whom only one patient conversed, showing new inflammatory signs at follow-up. Imaging of the spine was repeated in 15 out of 28 patients with a negative baseline MRI of the spine (53.6%), of whom none showed new lesions after 6 months.
Table 2SPARCC scores of the MRIs of 27 patients showing signs of inflammation, stratified for gender
Positive MRI (27 patients) (%) | 45.5 | 33.3 |
SIJ (21 patients) (%) | 37.5 | 25.0 |
Spine (9 patients) (%) | 20.0 | 18.5 |
SIJ and spine (3 patients) (%) | 3.0 | 5.6 |
SPARCC score in positive MRI (median, IQR) (27 patients) |
SIJ (median score 10.0 (4.0–25.0)* | 14 (2.3–25.0) | 10 (6.5–22.5) |
Spine (median score 10.0 (7.0–16.0) | 11 (8.5–25.6) | 8.0 (5.5–14.5) |
Conversion to positive MRI after 6 months follow-up (1 out of 21 patients)* |
SIJ N (%) | 0 | 1 (4.7%) |
SPARCC score
Patients with a positive MRI at baseline showed a median SPARCC score of the SIJ of 10.0 (IQR 4.0–25.0) and for the spine of 10.0 (IQR 7.0–16.0). Although not significant, male patients revealed a higher median SPARCC score of the SIJ and spine compared with females, 14.0 (IQR 2.3–25.0) vs. 10.0 (IQR 6.5–22.5) and 11.5 (IQR 8.5–25.6) vs. 8.0 (IQR 5.5–14.5), respectively (Table
2).
Comparison of MRI outcomes
Only a lower MASES score was significantly associated with a positive MRI outcome in logistic regression analyses (
β = − 0.02, 95% CI [− 0.04; − 0.01],
p = 0.004) (Table
1). Adjustment for sex, NSAID use at baseline and HLA-B27 status made no difference in the found association.
Structural changes
Overall, 17 MRIs of the spine and SI joints showed structural changes in 14 patients (20%), of whom 11 patients were male. The majority of these patients (N = 11) showed a combination of inflammatory and structural lesions in both the spine and SIJ. The most frequently recorded structural change was fat infiltration in both the spine (5 patients) and SIJ (1 patient). One patient had fatty infiltration in both the spine and SIJ (global fat infiltration). In the spine, fatty infiltration was found at several places, such as antero-inferior endplates, anterior corner and postero-superior endplate ranged L3–S1. Two patients showed doubtful erosions in the lower ilium. In addition, Schmorl’s nodes were seen in three patients located in the Th8–Th12 region of the spine.
Importantly, even in patients with a negative MRI (N = 3), several structural changes were noted. In two patients, fat infiltration was observed in the spine, whereas one patient showed Schmorl’s nodes at the superior endplates of Th8 and Th11.
Sacroiliitis on MRI according to the ASAS criteria
Sacroiliitis on MRI was present in 21 patients, of whom 11 patients showed unilateral and 10 patients bilateral sacroiliitis. Although not significant, more male patients had sacroiliitis compared with females, 37.5% vs. 21.6%, respectively.
ASAS classification of axial SpA
Twenty-six patients did not fulfil the nr-axSpA criteria, although the clinical presentation was highly suspicious of axial SpA. Twenty-three patients (52.3%) only fulfilled the “clinical arm”. In addition, 21 of the 44 patients (47.7%) fulfilled the “imaging arm” of the ASAS criteria, of whom 11 patients also fulfilled the criteria for the “clinical arm”. More male patients fulfilled the ASAS criteria imaging arm compared with females, 39.4% vs. 27.0%.
Discussion
In 69 patients with IBP and at least two SpA features and a high disease activity, 39% of patients showed signs of active inflammation (BME) according to the SPARCC score on MRI scans, primarily of the SI joints (88%) and a few of the spine. Only one patient conversed from a negative MRI at baseline to a positive MRI of the SI joints after 6 months, whereas no new lesions of the spine were detected after follow-up. Structural lesions, mainly of the spine, were present in 20% of the patients, most often in combination with signs of active inflammation, both in the spine and SIJ, but also in three patients without BME.
The number of positive MRIs is comparable with that in other study results in IBP patients, which showed prevalence between 26 and 41% [
4,
5]. The difference might be explained by the fact that our population had a high disease activity and shows results that are comparable with baseline data from clinical trials with biologicals, showing positive MRIs in 67%, 54% or 48% of the axial SpA patients [
15‐
17]. However, in the SPACE cohort, which included patients with chronic back pain (> 3 months, < 2 years and onset < 45 years), a positive MRI of the SIJ was found in only 25% of the patients [
18], which is much lower compared with our findings (39%). This difference can be explained by the high disease activity on our group, the presence of more SpA features, the addition of the MRI spine, which was positive in 19% of the patients with negative SIJ images, and the use of gadolinium, an intravenous contrast that enhances the quality of the MRI. The use of intravenous contrast in MRI scans of the spine and SI joints is a method that was used in the past. In selected cases, when high STIR signal in the joint is the only finding, gadolinium-enhanced images may help to confirm the presence of synovitis. However, in our study, this was not the case and the use of gadolinium for the axSpA images is abandoned nowadays.
The level of inflammation, measured with the SPARCC score, showed a mean score of 10.0 for the SI joints and 10.0 for the spine. Comparison with other studies in nr-axSpA showed contradictory results. Two studies showed comparable results: 7.2 and 7.4 for SIJ and 7.2 for spine [
19,
20], whereas two others showed lower SPARCC scores: SIJ 4.7 and 4.9 and spine 4.3 and 4.6, respectively [
15,
21]. There were no demographical features or baseline data (e.g. disease activity) that could explain the differences with our study results.
Only one patient (4.7%) with a negative MRI at baseline conversed to a positive MRI after 6 months. Other studies showed comparable numbers, 4–15%, of conversion of negative to positive MRIs [
4,
18]. These low numbers of conversion of a negative to a positive MRI after a short interval period indicate that it is not efficient to repeat a MRI within 6 months. These results were confirmed by the SPACE cohort, which indicated that repetition of MRI scans at 3 months and 1 year was not useful [
22].
Assessment of gender differences revealed that male patients, in general, more frequently had a positive MRI compared with females, 45.5% vs. 33.3%, respectively. In addition, the majority of patients with structural lesions was male (11/14 = 78.6%), which corresponds to a study by Maksymowych [
23]. These results are in line with the limited studies available assessing gender differences and MRI findings in nr-axSpA patients, which indicate that male gender, especially in the case of HLA-B27 positivity, is a predictor for a positive MRI outcome [
4]. Assessment of gender differences in the SPARCC scores in our study revealed that male patients had a higher median SPARCC score of the SIJ and spine compared with females, 14.0 vs. 10.0 and 11.5 vs. 8.0, respectively. Consistently, male patients also showed more often sacroiliitis at MRI, according to the ASAS definition, compared with females, 37.5% vs. 21.6%.
The question remained if MRI of the spine had an additional value to the MRI of the SIJ. In our own study, the number of positive MRIs of the spine was almost 20%. In addition, only three patients presented with a positive MRI of both the spine and SIJ. These results might indicate an additional value for the MRI of the spine. However, these numbers are in contradiction with a couple of other studies that assessed the diagnostic value of MRI of the spine [
24,
25]. Weber et al. revealed that the combined MRI (spine and SIJ) seemed to increase the percentage of identifications of nr-axSpA patients and also showed false positive results in an equal percentage in the control groups (non-specific back pain and inflammatory back pain patients). These misclassifications neutralized the additional diagnostic value of combined MRI in patients with nr-axSpA and seemed to have no contribution to the diagnosis [
24,
25].
Our study included a unique population of patients suspected of nr-axSpA with a high disease activity (BASDAI ≥ 4). For this reason, our results differ slightly from those of other studies conducted in a population that fulfilled the ASAS criteria. However, the numbers of specific SpA features were too small to assess them for possible associations with a positive or negative MRI. In this study, we have used the ESSG criteria and BASDAI instead of the ASAS classification criteria and ASDAS response, which we would have chosen nowadays. However, the study was developed in a period (2004) when these classification criteria and outcome parameters were much less often used as they currently are. In addition, as we mentioned in the “Introduction”, the MRI images of the SI joints are one of the major criteria in the ASAS classification criteria, whereas the primary aim of our study was to find out how often these images were positive in cases with a high risk at axial SpA. Considering the current debate around the value of all separate classification parameters in axial SpA, the MRI results of a slightly different group of back pain patients might help in the discussion around the added value of MRI in this group from a different perspective.
This study has several limitations. Apart from the inclusion criteria and disease activity parameters, which differ from the currently used criteria, we had only one assessor of the MRIs, who performed the SPARCC scores, and all MRIs were also assessed by the musculoskeletal radiologist of the university medical centre. In addition, we have not repeated the MRIs in all patients after 6 months, but only in those who did not show inflammatory lesions at baseline. Another limitation is the lower number of patients who underwent the MRI of the spine compared with the SIJ because they refused to undergo this procedure. However, the number of images of the SIJ is high enough to draw conclusions on the presence of inflammation in this group with high disease activity.
In summary, the results of this study show that in this specific group of patients with inflammatory back pain, a high BASDAI score and those who are either HLA-B27 positive and have one additional SpA feature or HLA-B27 negative with two additional SpA features have a number of positive MRI results of the SI joints. All patients with a positive MRI were included in a placebo-controlled trial with etanercept (the PREVAS study) of which the results will be presented soon. In our opinion, the MRI of the spine is of limited value in addition to the MRI SIJ for the assessment of disease activity and repetition of the MRI after 6 months of the SI joints, in case of absence of inflammation, is not warranted either.
In conclusion, almost 40% of the patients with inflammatory back pain and high disease activity showed inflammatory lesions on MRI of the SIJ and/or spine, which occurred more often in males compared with females. In most cases (95.3%), a MRI without inflammatory lesions remained negative after 6 months, which suggests that a second MRI scan after only 6 months is not valuable.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.